Recombinant Human Chondroitin sulfate proteoglycan 5 (CSPG5)

What is the basic structure of human CSPG5 protein?

Human Neuroglycan C (NGC/CSPG5) is a 120-150 kDa type I transmembrane glycoprotein belonging to the neuregulin family. It is synthesized as a 566 amino acid precursor containing a 30 aa signal sequence, a 393 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 122 aa cytoplasmic region. The ECD contains one chondroitin sulfate (CS) attachment domain (aa 34-272) with CS attachment at Ser117, one EGF-like domain (aa 371-413), two potential sites for N-linked glycosylation, and twelve potential sites for O-linked glycosylation .

What are the known splice variants of human CSPG5?

Three isoforms have been identified for human CSPG5. Isoform 1 is the canonical long form. Isoform 2 has a deletion of amino acids 487-513, while isoform 3 has an alternative start site at Met139 and shares the same deletion as isoform 2. Phosphorylation likely occurs at Ser249, and proteolysis can generate a 75 kDa soluble fragment .

Where is CSPG5 primarily expressed?

CSPG5 is predominantly expressed in nervous tissue. It has been detected on retinal ganglion cells, cerebellar Purkinje cells, and hippocampal neurons . Recent studies have also identified CSPG5 expression in lens epithelial cells, suggesting a wider expression pattern than initially thought .

What are the optimal storage conditions for recombinant CSPG5 protein?

Recombinant human CSPG5 protein should be stored at -20 to -70°C for long-term stability. After reconstitution, the protein maintains stability for approximately 1 month at 2-8°C under sterile conditions, or up to 6 months at -20 to -70°C. It's critical to avoid repeated freeze-thaw cycles by using a manual defrost freezer .

How should recombinant CSPG5 be reconstituted for experimental use?

Lyophilized recombinant CSPG5 should be reconstituted at a concentration of 500 μg/mL in PBS. The reconstituted protein should be handled with care to maintain its biological activity. For carrier-free versions, which do not contain BSA, special attention should be paid to protein concentration and stability concerns .

What detection methods are most effective for CSPG5 in biological samples?

Western blotting has proven effective for detecting CSPG5, typically revealing bands at approximately 120 kDa and 150 kDa corresponding to the glycoprotein and proteoglycan forms, respectively. For quantitative detection, sandwich ELISA assays have been developed with detection ranges of 0.156-10 ng/ml for human CSPG5 and 0.312-20 ng/ml for rat CSPG5, with sensitivities of <0.094 ng/ml and 0.117 ng/ml, respectively .

What signaling pathways does CSPG5 activate in neural cells?

CSPG5 functions as a growth and differentiation factor in neuritogenesis through multiple signaling pathways. Research has demonstrated that the recombinant ectodomain of CSPG5 core protein enhances neurite outgrowth from rat neocortical neurons via phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) signaling pathways. Additionally, CSPG5 acts as a growth factor by directly binding ErbB3 tyrosine kinase and transactivating ErbB2 .

How does CSPG5 differ from other chondroitin sulfate proteoglycans in function?

Unlike many CSPGs that inhibit axonal growth and neuroplasticity, CSPG5 appears to have neurite-promoting properties. While CSPGs like aggrecan and versican are broadly expressed and play critical roles in chondrogenesis and joint morphogenesis, CSPG5 has a more restricted expression pattern primarily in nervous tissue and appears to function more in neural development and synaptic organization .

What are the considerations for using CSPG5 antibodies in immunohistochemistry?

When using antibodies against CSPG5 for immunohistochemistry, researchers should be aware that CSPG5 forms perisynaptic matrix rings that often appear at the peripheral margin of perineuronal nets. For optimal visualization of these structures, it's recommended to use tissue sections no thicker than 20 μm and to perform antigen retrieval. The staining pattern should be evaluated in conjunction with markers for glutamatergic and GABAergic terminals, as CSPG5 typically concentrates around these structures in mature neural tissue .

How can MS-based glycoproteomics be used to study CSPG5 glycosylation patterns?

Advanced glycoproteomic approaches for CSPG5 involve trypsin digestion of CSPG-containing samples, followed by CS glycopeptide enrichment using strong-anion-exchange (SAX) chromatography. The enriched glycopeptides are then incubated with chondroitinase ABC to depolymerize the CS polysaccharides, generating residual structures still attached to the peptides. Analysis is performed by nano-scale reversed-phase liquid chromatography tandem mass spectrometry (nLC-MS/MS) in positive mode, with data evaluated through proteomic database searches adjusted for glycopeptide identification. For optimal results, use controlled digestion times with chondroitinase ABC to yield peptide-attached CS structures of 6 to 18 monosaccharides in length, which enables core protein-specific CS structural analysis .

What is the role of CSPG5 in steroid-induced cataracts?

Research has demonstrated that CSPG5 expression is significantly upregulated in the lens epithelium of steroid-induced cataract (SIC) patients compared to age-related cataract patients. Functional studies using dexamethasone-treated human lens epithelial (HLE-B3) cells have shown that downregulation of CSPG5 suppresses steroid-induced epithelial-mesenchymal transition (EMT)-related protein expression and cellular motility. The effect appears to be mediated through transcription factors EZH2 and B-Myb, which regulate CSPG5 expression. These findings suggest CSPG5 as a potential therapeutic target for the prevention and treatment of SIC .

How does CSPG5 contribute to synaptic organization in the brain?

CSPG5 forms perisynaptic matrix rings around glutamatergic and GABAergic terminals in the mature brain. Electron microscopy and analysis of synaptosomal fractions have shown that CSPG5 accumulates around and is associated with synapses. In vitro analyses suggest that neurons, rather than astrocytes, primarily express CSPG5 in rat primary neocortical cultures. CSPG5 produced by transfected neuroblastoma cells appears at endings and contact points of neurites. Notably, in human subjects, CSPG5 expression shifts in brain areas of the default mode network of suicide victims, potentially reflecting an impact in the pathogenesis of psychiatric diseases .

How can the contradictory effects of different CSPGs be reconciled in therapeutic approaches?

While many CSPGs inhibit axonal growth and neuroplasticity after CNS injury, CSPG5 appears to promote neurite extension. This apparent contradiction needs careful consideration when developing therapeutic approaches. A potential solution is to target specific sulfation patterns rather than entire proteoglycan molecules. Research has identified the 4-sulfation (4S) at the non-reducing end of CS GAG chains as particularly important for the inhibitory actions of many CSPGs . Targeted approaches that modify specific sulfation patterns while preserving beneficial CSPG functions (like those of CSPG5) represent a promising direction for therapeutic development.

What are the challenges in studying CSPG5-specific interactions with growth factors?

Studying specific interactions between CSPG5 and growth factors presents significant challenges due to the complexity of CS chains and potential overlapping binding sites. Advanced approaches include using quantitative binding curves between growth factors and different CS GAG chains (with CS-4, CS-6, and unsulfated CS-0 motifs) to determine binding affinity (Kd) and binding capacity (Bmax). Mutations in the Cardin-Weintraub motif of growth factors can help determine if interactions are primarily mediated through this motif. Additionally, quantitative immunoprecipitation with specific CSPG5 antibodies can demonstrate direct interactions .

How can researchers modify CSPG5 glycosylation for specific functional studies?

Researchers seeking to study the effect of specific glycosylation patterns on CSPG5 function can employ several approaches. One strategy is to use glucosamine derivatives and xylosides that interfere with CSPG biosynthesis. For example, per-O-acetylated 4,4-difluoro-N-acetylglucosamine (Ac-4,4-diF-GlcNAc) has been shown to reduce CSPG levels and inflammatory responses in experimental models. Additionally, site-directed mutagenesis of the Ser117 CS attachment site or other glycosylation sites can generate CSPG5 variants with altered glycosylation. These modified proteins can then be used in functional assays to determine the contribution of specific glycan structures to CSPG5 activity .

What controls should be included when studying CSPG5 function in cellular models?

When investigating CSPG5 function in cellular models, several controls are critical:

• Expression controls: Include both the glycosylated (150 kDa) and non-glycosylated (120 kDa) forms of CSPG5 to distinguish proteoglycan-specific from core protein effects

• Chondroitinase controls: Treatment with chondroitinase ABC to remove CS chains helps determine if observed effects are dependent on glycosylation

• Domain-specific constructs: Use constructs expressing only the ECD, EGF-like domain, or cytoplasmic domain to identify domain-specific functions

• Signaling pathway inhibitors: Include PI3K inhibitors (e.g., LY294002) and PKC inhibitors when studying CSPG5-mediated neurite outgrowth to confirm pathway involvement

How should researchers interpret contradictory findings regarding CSPG5 effects across different neural cell types?

Contradictory findings regarding CSPG5 effects across different neural cell types may arise from several factors:

• Developmental stage: CSPG5 effects may vary depending on the developmental stage of the cells being studied

• Glycosylation differences: The degree and pattern of CS chain sulfation can significantly alter CSPG5 function

• Receptor expression: Different neural cell types may express varying levels of receptor tyrosine kinases (particularly ErbB3) that interact with CSPG5

• Extracellular environment: The composition of the surrounding ECM can modulate CSPG5 function

To address these contradictions, researchers should:

• Clearly characterize the developmental stage of cells being studied

• Analyze CSPG5 glycosylation status in their experimental system

• Quantify expression of potential CSPG5 receptors

• Consider the influence of other ECM components present in their model system